Navigation Links
Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting

edicine, the Dana-Farber Cancer Institute and National Cancer Institute/CTEP are authors.

About Romidepsin

Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-474-2825.

Contact

Media
KMorrisPR
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com
or
Gloucester Pharmaceuticals
Beverly Holley, 617-583-1362
beve
'"/>





Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
3. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:9/4/2015)... 2015  IGI Laboratories, Inc. (NYSE MKT: IG), a ... pharmaceutical company, today announced it has submitted its seventh ... and Drug Administration (FDA) of 2015, which brings the ... the FDA to twenty-nine. Jason Grenfell-Gardner ... believe our current pipeline of twenty-nine submissions, exclusive of ...
(Date:9/4/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/gvzjt8/investigation ) ... China,s Sodium Ibandronate Market, 2010-2019" report to their offering. ... the trade name of Bondronat in Germany ... ibandronate was approved by the FDA to come into the ... name of Boniva. However, since drug makers later developed more ...
(Date:9/4/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced its financial results for the fiscal ... of recent Company highlights and expected near-term milestones. ... update conference call and live webcast for investors, analysts ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2Investigation Report on China's Sodium Ibandronate Market 2010-2019 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8
(Date:9/4/2015)... ... September 04, 2015 , ... ... taking place in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & ... 2015 symposium are doctors and researchers at the top of their field and ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... of its first neighborhood created specifically for adults with intellectual, developmental and acquired ... Metro area and feature 30 cottage or “pocket” homes. In this community, adults ...
(Date:9/4/2015)... ... ... Steven Winter Associates, Inc., (SWA) is pleased to announce ... Residential Award of Merit by the Connecticut Green Building Council (CTGBC) for its ... field of submissions, the net-zero energy residence will be honored at the 2015 ...
(Date:9/4/2015)... Abilene, Texas (PRWEB) , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer ... what he says are prophetic details involving the Pope’s upcoming trip to the United States. ... and details what his role with the Vatican and society is. Yisrayl also provides the ...
(Date:9/4/2015)... Miami, Florida (PRWEB) , ... September 04, 2015 ... ... air ambulance and medical assistance company today announced that it has entered into ... Last week, EMED signed an agreement to bridge the link between American healthcare, ...
Breaking Medicine News(10 mins):Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6
... the rise among patients who suffer from acute illness. The ... of Hygiene and Tropical Medicine, //said that they wanted to ... ,The Lancet studied and analyzed the 3 million ... 3,755 a clot on the lung. The London team found ...
... relief FDA, the U.S. health regulators, gave their nod to ... organ rejection in heart transplant patients.// ,The drug, Astellas ... liver and kidney transplants. ,Dr. Steven Galson, head ... "The doctors who perform approximately 2,200 heart transplants in the ...
... In a news study it has been shown that babies ... not have the much feared consequences and is safe. The ... ,The theory was researched and assessed by unconnected Nottingham researchers ... method was pioneered by controversial Stoke-based paediatrician Professor David Southall. ...
... to a village in Bihar was left for herself to cremate ... nobody turned up// give a helping hand. The widow dragged his ... rites herself. ,Grief-stricken Dhanua Devi (named changed), a 36-year-old resident ... visited her thatched hut to console her. ,A mother ...
... to the tune of ?4m or more will be allocated ... spending should take care of containing// the unhealthy trend, atleast ... up by almost 50%. ,A senior medical post ... with suicidal tendencies, according to Mr Woodward. To enable this ...
... dismissed increased risk of heart attack associated with Vioxx, has ... 'out of the mainstream' as it is based on biased ... ,Thomas Cona and John Mcdarby have sued the ... in heart attacks. More than 10, 000 different lawsuits has ...
Cached Medicine News:Health News:DVT Risk Increased After Acute Infections 2Health News:Doctor Grilled In Court For False Report About Vioxx Health Risk 2
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
... Coronary Stent System is Guidant's first in ... Cobalt chromium is stronger and more radiopaque ... stent can have similar strength and visibility ... struts that are only .0032" thick. Thinner ...
Medicine Products: